Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom collaborative trial of ovarian cancer screening
Menon, U., Ryan, A., Kalsi, J., Gentry-Maharaj, A., Dawnay, A., Habib, M., Apostolidou, S., Singh, N., Benjamin, E., Burnell, M., +26 more...Davies, S., Sharma, A., Gunu, R., Godfrey, K., Lopes, A., Oram, D., Herod, J., Williamson, K., Seif, M. W., Jenkins, H., Mould, T., Woolas, R., Murdoch, J. B., Dobbs, S., Amso, N. N., Leeson, S., Cruickshank, D., Scott, I., Fallowfield, L., Widschwendter, M., Reynolds, K., McGuire, A.
, Campbell, S., Parmar, M., Skates, S. J. & Jacobs, I.
(2015).
Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom collaborative trial of ovarian cancer screening.
Journal of Clinical Oncology,
33(18), 2062-2071.
https://doi.org/10.1200/JCO.2014.59.4945
, Campbell, S., Parmar, M., Skates, S. J. & Jacobs, I.
(2015).
Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom collaborative trial of ovarian cancer screening.
Journal of Clinical Oncology,
33(18), 2062-2071.
https://doi.org/10.1200/JCO.2014.59.4945
Cancer screening strategies have commonly adopted single-biomarker thresholds to identify abnormality. We investigated the impact of serial biomarker change interpreted through a risk algorithm on cancer detection rates.
